Compared to other MAGL inhibitors such as JZL184 and MJN110, which did not alter the anticancer activities of paclitaxel (Curry et al., 2018), pristimerin might have an advantage because it had an additive effects on paclitaxel’s anticancer activities against breast cancer cell lines (Lee et al., 2018). Here, MGLL is linked to breast carcinoma.